Trial Profile
A Randomized, Open-Label Comparative Study of Combination Therapy With Cyclophosphamide and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine With or Without Trastuzumab for the Treatment of Metastatic Breast Cancer That Does NOT Over-express HER-2/Neu
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Breast cancer vaccine; Cyclophosphamide
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 15 Feb 2019 Status changed from active, no longer recruiting to completed.
- 24 Sep 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.
- 24 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.